[Old and new anticoagulants. Antidotes and measures for acute hemorrhaging and urgent interventions].
Anticoagulation medications are frequently used for primary and secondary treatment of several thrombo-embolic disorders. An important side effect of all anticoagulants is hemorrhagic diathesis which necessitates acute treatment, ideally using medicinal therapy with an antidote. Much experience has been gained in treating bleeding while on traditional anticoagulants, such as heparins and vitamin K antagonists by the use of antagonists. A multitude of factor-specific anticoagulants have recently been introduced or will soon receive approval. With this new generation of anticoagulants no valid laboratory parameters or effective antagonists are presently available. Due to a lack of adequate studies regarding acute treatment this can at present only be carried out on a symptomatic basis.
Lancé
M
M
Klinik für Anästhesiologie und Schmerztherapie, Universitätsklinikum MUMC+, AZ Maastricht, The Netherlands. marcus.lance@mumc.nl
Stessel
B
B
Hamulyák
K
K
Marcus
M A
MA
D000208:Acute Disease; D000925:Anticoagulants / Q000037:antagonists & inhibitors* / Q000145:classification / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use*; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced* / Q000628:therapy*; D006493:Heparin / Q000009:adverse effects / Q000627:therapeutic use; D006494:Heparin Antagonists / Q000627:therapeutic use; D006801:Humans; D011134:Polysaccharides / Q000627:therapeutic use; D011516:Prothrombin / Q000037:antagonists & inhibitors; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D000931:Antidotes; D065427:Factor Xa Inhibitors; D006494:Heparin Antagonists; D011134:Polysaccharides; D014812:Vitamin K; D011516:Prothrombin; D006493:Heparin